157 related articles for article (PubMed ID: 31709853)
61. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.
Kawazoe H; Uozumi R; Murakami A; Yamashita M; Kobayashi-Taguchi K; Kusakabe E; Yamasawa H; Yakushijin Y; Nakamura T; Kamei Y
Sci Rep; 2018 Nov; 8(1):16232. PubMed ID: 30389996
[TBL] [Abstract][Full Text] [Related]
62. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
Yang CK; Wu CE; Liaw CC
Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
[TBL] [Abstract][Full Text] [Related]
63. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
64. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
65. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
[TBL] [Abstract][Full Text] [Related]
67. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
69. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
70. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
[TBL] [Abstract][Full Text] [Related]
71. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
72. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
73. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
74. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
75. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Rapoport BL
Curr Med Res Opin; 2014 Sep; 30(9):1875-81. PubMed ID: 24911369
[TBL] [Abstract][Full Text] [Related]
77. Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients.
Kono T; Ueda T; Takumida M; Furuie H; Hamamoto T; Takeno S; Hirakawa K
Acta Otolaryngol; 2018 Oct; 138(10):921-925. PubMed ID: 30016902
[TBL] [Abstract][Full Text] [Related]
78. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
79. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
80. New antiemetic drugs.
Roila F; Fatigoni S
Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]